The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Soligenix's share price is $0.4173. Soligenix's Book Value per Share for the quarter that ended in Dec. 2023 was $0.24. Hence, Soligenix's PB Ratio of today is 1.72.
The historical rank and industry rank for Soligenix's PB Ratio or its related term are showing as below:
SNGX'
s PB Ratio Range Over the Past 10 Years
Min: 0.74 Med: 3.68 Max: 802.26
Current: 1.74
During the past 13 years, Soligenix's highest PB Ratio was 802.26. The lowest was 0.74. And the median was 3.68.
SNGX's PB Ratio is ranked better than 61.83% of 1310
companies
in the Biotechnology industry
Industry Median: 2.385
vs SNGX: 1.74
During the past 3 years, the average Book Value Per Share Growth Rate was -49.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Soligenix was 57.80% per year. The lowest was -63.30% per year. And the median was -12.35% per year.
Back to Basics: PB Ratio
Soligenix PB Ratio Historical Data
The historical data trend for Soligenix's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Soligenix's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's PB Ratio distribution charts can be found below:
* The bar in red indicates where Soligenix's PB Ratio falls into.
Soligenix PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Soligenix's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Soligenix PB Ratio Related Terms
Thank you for viewing the detailed overview of Soligenix's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNGX has been successfully added to your 